A pilot clinical trial to determine the safety and effectiveness of coded Siddha formulations Nuflm-1 capsule, Spln -2 softgel and Rudn oil -3 in the management of cervical disc disorder with radiculopathy (M50.10) and Sciatica (M54.3) - NI

il0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年4月1日

试验速览

暂无简介。

•Males or females, ages 18 to 65, are able and willing to provide written informed consent to participate in the study.
•Leg pain radiating to or below the knee in a dermatomal pattern, diagnosed as being due to sciatica or lumbar or lumbosacral radiculopathy, the onset of which occurred 2 to 12 weeks prior to initiation of study treatment.
•Leg pain severity on a screening Categorical Pain Intensity Rating (for the prior 3 days period) of at least 4 in the numerical rating scale. Leg pain should be more severe than back pain on Numerical rating scale of pain at screening.
•Positive straight leg raising (SLR) test.
•Pain, paresthesia or numbness in the upper-limb with cervical or periscapular pain for less than 3 months.
•At least one neurological sign (dermatomes, myotomes or reflexes) of an inferior motoneuron lesion to the upper-limb.
•Positive responses to at least 3 of the 4 following clinical tests: Spurling Test, Upper
•Limb Tension Test, Cervical Distraction Test, and less than 60° of cervical rotation
•on the impaired side.

发起方